Other names: DKFZp434N231; KIAA0444 HGNC (Hugo): CHD5 Location: 1p36.31
Transcription
The CHD5 cDNA sequence spans 9646 bp, with a 5' UTR of 100 bp, a single open reading frame of 5865 bp, and a 3' UTR of 3681 bp (Thompson et al., 2003) .
Pseudogene
None known.
Protein

Description
The 5' portion of CHD5 is predicted to contain two zinc-fingers of the PHD class (amino-acid positions 345-390 and 418-463), followed closely by two chromodomains (510-525 and 596-625) . PHD zincfinger motifs are thought to play roles in chromatinassociated transcriptional regulation, whereas chromodomains are frequently observed in proteins involved in recruitment of transcriptional regulatory complexes. The central portion of the protein includes a predicted DEAH-box type helicase domain (703-999) and a putative SNF2 domain (1054-1138). DEAH ATP helicases are ATP-dependent and are usually associated with nucleic acid unwinding. SNF2 domains are commonly observed in, although not restricted to, proteins involved in chromatin unwinding, DNA repair and recombination, and transcriptional regulation. A number of potential nuclear localization signals are also present (50-67, 54-71, 97-114, 100-117, 240-257, 253-270, 918-935) (Thompson et al., 2003) .
Expression
Detectable expression of CHD5 was limited to all neural-derived tissues (fetal brain, total brain, cerebellum) and adrenal gland, with no expression detected in placenta, liver, fetal liver, spleen, bone marrow, thyroid, thymus, salivary gland, stomach, pancreas, small intestine, colon, or prostate (Thompson et al., 2003; Okawa et al., 2008) .
Localisation
Intracellular expression is preferentially nuclear (unpublished observations, GMB).
Function
CHD family proteins are thought to play a role in chromatin remodeling. CHD5 is most homologous to CHD3 and CHD4, which participate in the formation of a Nucleosome Remodeling and Deacetylation (NuRD) complex, in association with other proteins. This complex is generally thought to repress transcription.
The functional domains of the chromodomain-helicase-DNA binding protein 5 (CHD5) are shown above. There are two PHD type zinc fingers, two chromodomains, a split DEAH-box ATP-helicase domain, and a poorly defined DNA binding domain.
Homology
Strongest homology to CHD3 and CHD4, with weaker homology to CHD1, CHD2, CHD6, CHD7, CHD8 and CHD9.
Mutations
Note
No examples of homozygous inactivation have been identified, and no nonsense or frameshift mutations have been identified in any cancers to date. Several missense mutations have been detected, but it is unclear if any of these have an effect on the function of the protein Fujita et al., 2008; Ng et al., 2008) .
Implicated in
Neuroblastoma Note CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system (Thompson et al., 2003) . CHD5 maps to 1p36.3, a region of consistent deletion in neuroblastoma and other tumors (White et al., 2005) . CHD5 is one of 23 genes that map to the 800 Kb region of consistent deletion on 1p36.3 in an analysis of over 1,200 primary neuroblastomas . Functional analysis of CHD5 after transfection into neuroblastoma cell lines demonstrates that CHD5 functions as a tumor suppressor gene, suppressing both clonogenicity and tumorigenicity. The promoter was methylated especially between -780 and -450 in neuroblastoma cell lines with 1p36 deletions, but not those with two copies of CHD5. Furthermore, high CHD5 expression is highly correlated with favorable clinical and biological risk features as well as outcome in a panel of 101 primary tumors . These data suggest that CHD5 is a bona fide tumor suppressor gene in neuroblastomas. Deletion of 1p36 is associated with loss of CHD5 expression, and the CHD5 promoter is preferentially methylated in lines with 1p36 deletion. Furthermore, low CHD5 expression is associated with a worse outcome in neuroblastoma patients.
Gliomas
Note CHD5 is one of several genes that maps to the 700 Kb region of consistent deletion in 17 glioma cell lines (Law et al., 2005) . Loss of CHD5 expression is associated with deletion of 1p36 in a panel of 54 glial tumors (Bagchi et al., 2007) . These data are consistent with a role for CHD5 as a tumor suppressor gene in these tumors.
Melanoma
Note A subset of malignant melanoma families show linkage to 1p36, and CHD5 is a tumor suppressor gene that maps to this region. However, screening of CHD5 for mutations in eight melanoma-prone families linked to 1p36 revealed no deleterious coding or splice site mutations (Ng et al., 2008) . This suggests that CHD5 is not a major melanoma susceptibility gene, at least in the families screened.
Ovarian cancer
Note
Mutation and methylation analysis of CHD5 gene was undertaken in 123 ovarian cancers, whereas no such mutations were identified in 60 primary breast cancers. Somatic heterozygous missense mutations were identified in 3 samples, and promoter methylation was identified in another 3 of 45 samples tested (Gorringe et al., 2008) . These data suggest that CHD5 may play a role as a tumor suppressor gene in a subset of ovarian cancers, but there may be other suppressors on 1p36 as well.
Colorectal cancer
Note
The methylation status of a set of cancer-related genes was studied in 102 colon cancers from Iranian and African-American populations (51 each). The methylation status of the promoters of three genes (CHD5, ICAM5 and GPNMB) was significantly higher in cancers from the African-American population compared to the Iranian patients (Mokarram et al., 2009 ). This suggests that these genes may play a role in the incidence or aggressiveness of colorectal cancer in this population.
Gastric cancer
Note
The methylation status of the CHD5 promoter was examined in 15 primary gastric cancers and 7 gastric cancer cell lines. CHD5 expression was downregulated in 7/7 cell lines, and methylation of the promoter was
